US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

XBIT

XBiotech (XBIT)

XBiotech Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XBIT

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
10/05/2024	10:27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
07/02/2024	11:36	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:XBIT	XBiotech Inc
05/01/2024	09:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XBIT	XBiotech Inc
04/01/2024	08:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XBIT	XBiotech Inc
04/01/2024	08:00	GlobeNewswire Inc.	XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	NASDAQ:XBIT	XBiotech Inc
14/11/2023	08:00	GlobeNewswire Inc.	Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis	NASDAQ:XBIT	XBiotech Inc
26/09/2023	08:00	GlobeNewswire Inc.	XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	NASDAQ:XBIT	XBiotech Inc
30/08/2023	08:00	GlobeNewswire Inc.	XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	NASDAQ:XBIT	XBiotech Inc
08/08/2023	10:47	GlobeNewswire Inc.	XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial	NASDAQ:XBIT	XBiotech Inc
26/06/2023	07:48	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
23/06/2023	14:04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XBIT	XBiotech Inc
20/06/2023	08:20	Edgar (US Regulatory)	Amended Tender Offer Statement by Issuer (sc To-i/a)	NASDAQ:XBIT	XBiotech Inc
22/05/2023	08:00	GlobeNewswire Inc.	FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients	NASDAQ:XBIT	XBiotech Inc
17/05/2023	08:22	Edgar (US Regulatory)	Tender Offer Statement by Issuer (sc To-i)	NASDAQ:XBIT	XBiotech Inc
17/05/2023	08:00	GlobeNewswire Inc.	XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares	NASDAQ:XBIT	XBiotech Inc
10/05/2023	14:42	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XBIT	XBiotech Inc
28/04/2023	11:38	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:XBIT	XBiotech Inc
28/04/2023	11:33	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:XBIT	XBiotech Inc
10/02/2023	11:22	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XBIT	XBiotech Inc
13/10/2022	11:46	GlobeNewswire Inc.	XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer	NASDAQ:XBIT	XBiotech Inc
20/06/2022	08:00	GlobeNewswire Inc.	XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study	NASDAQ:XBIT	XBiotech Inc
13/05/2022	14:17	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:XBIT	XBiotech Inc
28/04/2022	08:00	GlobeNewswire Inc.	XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cance	NASDAQ:XBIT	XBiotech Inc
15/03/2022	16:02	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:XBIT	XBiotech Inc
02/02/2022	08:00	GlobeNewswire Inc.	XBiotech Inks Clinical Manufacturing Deal	NASDAQ:XBIT	XBiotech Inc
13/12/2021	07:00	GlobeNewswire Inc.	FDA Approves XBiotech’s IND in Rheumatology	NASDAQ:XBIT	XBiotech Inc
28/10/2021	10:59	GlobeNewswire Inc.	XBiotech to Launch Novel Candidate Therapy for Stroke	NASDAQ:XBIT	XBiotech Inc
08/09/2021	08:00	GlobeNewswire Inc.	Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer	NASDAQ:XBIT	XBiotech Inc
30/08/2021	08:00	GlobeNewswire Inc.	XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director	NASDAQ:XBIT	XBiotech Inc
30/07/2021	10:03	GlobeNewswire Inc.	XBiotech Announces Payment of Dividend to Holders of Common Stock	NASDAQ:XBIT	XBiotech Inc

Showing the most relevant articles for your search:NASDAQ:XBIT

1 2 3 4 5 6 7 8 9 10 Próxima >

Vontobel Financial Produ...

Barclays Bank Plc Point ...

Sabrient Dividend Portfo...

Jpmorgan Chase Financial...

MCNB Banks (PK)

Vontobel Financial Produ...

Goldman Sachs Bank Usa P...

Cerrado Gold (QX)

Nelson Resources

Innovator US Equity Ultr...

Mitsui High tec (PK)

RSE Archive (GM)

Bathurst Resources

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones